| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Here's a roundup of top developments in the biotech space over the last 24 hours.
(Biotech Stocks Hitting 52-week Highs Oct. 8)
(Biotech Stocks Hitting 52-week Lows Oct. 8)
Selecta Biosciences Inc (NASDAQ:SELB) said it has entered into a research license and option agreement with IGAN Biosciences, Inc. to study Selecta's ImmTOR immune tolerance platform in combination with IGAN's immunoglobulin A protease for the treatment of IgA Nephropathy. Before exercising its option to enter into an exclusive license agreement, Selecta said it will conduct preclinical research to evaluate the utility of the combination of ImmTOR and IGAN's IgA protease.
The agreement necessitates Selecta making an initial payment to IGAN, and if it exercises its option to enter into an exclusive license agreement, IGAN will receive an additional payment and will be eligible for additional development, regulatory, and commercial milestone payments, as well as tiered royalties on net product sales, Selecta said.
The stock rose 24.35% to $2.40 in after-hours trading.
GenMark Diagnostics, Inc (NASDAQ:GNMK) announced preliminary third-quarter results, expecting revenues of $42.6 million, up 104% year-over-year. The consensus estimate for the quarter is $38.09 million. The company said its ePlex molecular diagnostic systems sales surged up 187% to $38.09 million. The company expects gross margin to expand from 34% in the third quarter of 2019 to 38-39%.
Separately, the company said it received emergency use authorization for its ePlex Respiratory Pathogen Panel 2. In less than two hours, the test provides results for more than 20 viruses and bacteria that cause common and often serious respiratory infections, including COVID-19, flu, bronchitis and the common cold, it added.
In after-hours trading, the stock was up 12.59% to $16.10.
Axovant Gene Therapies Ltd (NASDAQ:AXGT) said it has received rare pediatric disease designation from the FDA for AXO-AAV-GM1, an AAV9-based gene therapy delivered via a single intravenous administration that is in Phase 1/2 development for GM1 gangliosidosis.
The stock was rallying 7.55% to $4.13 in pre-market trading.
Emergent Biosolutions Inc (NYSE:EBS) announced the initiation of the Phase 3 clinical trial evaluating plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with COVID-19. The study is sponsored by the NIAID.
The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent's COVID-HIG, with a background therapy of remdesivir in all groups, Emergent said.
A joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will reviewAlkermes Plc's (NASDAQ:ALKS) NDA for olanzapine/samidorphan oral tablets for the proposed indications of schizophrenia and bipolar I disorder.
The committees will discuss the efficacy, safety, and benefit-risk profile of the combo treatment.
Kronos Bio, Inc., a clinical-stage biopharma engaged in the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, priced its initial public offering, or IPO, of 13.16 million shares of its common stock at $19.00 apiece, for raising gross proceeds of $250 million. The company had earlier estimated a price range of $16-$18.
The shares will begin trading on the Nasdaq under the ticker symbol KRON.
Spruce Biosciences, Inc., a biopharma focusing on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, priced its upsized IPO of 6 million shares at $15 per share, at the midpoint of the estimated price range of $14-$16. Gross proceeds from the offering are estimated at $90 million.
The shares will begin trading on the Nasdaq under the symbol SPRB.
Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Posted In: ACRS ADPT ALKS ALXN ARGX ARNA AXGT AZYO BCLI BIO CDNA CRDF CSTL DNLI EBS EXAS FATE GNMK HZNP IBB
